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Metronidazole has been used clinically for over 50 years as an antiparasitic and broad-spectrum anti-
bacterial agent effective against anaerobic bacteria. However resistance to metronidazole in parasites and
bacteria has been reported, and improved second-generation metronidazole analogues are needed. The
copper catalysed Huigsen azide-alkyne 1,3-dipolar cycloaddition offers a way to efﬁciently assemble new
libraries of metronidazole analogues. Several new metronidazole-triazole conjugates (Mtz-triazoles)
have been identiﬁed with excellent broad spectrum antimicrobial and antiparasitic activity targeting
Clostridium difﬁcile, Entamoeba histolytica and Giardia lamblia. Cross resistance to metronidazole was
observed against stable metronidazole resistant C. difﬁcile and G. lamblia strains. However for the most
potent Mtz-triazoles, the activity remained in a therapeutically relevant window.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
For over 50 years the 5-nitroimidazole antibiotic metronidazole
1 has been in clinical use as a broad-spectrum agent for treatment
of Gram-positive and Gram-negative anaerobic bacterial infections
as well as parasitic infections [1]. Reduction of the nitro group to
the nitro radical anion by electron carriers in an anaerobic envi-
ronment leads to decomposition to form toxic metabolites, which
cause DNA damage and nonspeciﬁc macromolecular damage
leading to cell death [2]. However, metronidazole resistance has
been observed in both parasites [3,4] and anaerobic bacteria [5,6].
Over the last ten years metronidazole has also been extensively
used to treat Clostridium difﬁcile infection (CDI), an intestinal
infection that causes life-threatening severe diarrhea, abdominaltration; Mtz, metronidazole;
resistant.
r).
d, Darra, Queensland, 4076,
r Masson SAS. This is an open accepain and fever [7]. The spores produced by C. difﬁcile are resistant to
heat and alcohol based disinfectants, complicating eradication and
promoting hospital-based outbreaks. Metronidazole is one of three
antibiotics routinely prescribed to treat the disease [8]. Metroni-
dazole is effective against mild tomoderate C. difﬁcile infection, but,
while not wide-spread, resistance has been observed in clinical
isolates [9]. To this end, the development of next generation
metronidazole analogues that can overcome resistance is thera-
peutically important.
Beena et al. previously reported the synthesis of metronidazole-
triazole conjugates (Mtz-triazoles) with potent activity (reported as
IC50 values 0.06e0.35 mg/mL) against the facultative anaerobic
bacteria Staphylococcus aureus, Staphylococcus epidermis, Escher-
ichia coli and Pseudomonas aeruginosa [10]. Metronidazole is
generally not active against Gram-negative and Gram-positive
facultative anaerobic bacteria, so the potent activities of Mtz-
triazoles observed by Beena et al. are suggestive of a different
mode of action to metronidazole. Given that the active 5-
nitroimidazole core (“warhead”) in metronidazole is maintained
in Mtz-triazoles, and that the hydroxyl group of metronidazole is
amenable to modiﬁcation [11] (Fig. 1), we reasoned that this classss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Metronidazole contains the 5-nitroimidazole warhead and a hydroxyl group
amenable to modiﬁcation.
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and parasites for which metronidazole is used as a treatment.
Therefore, we believed Mtz-triazoles warranted further investiga-
tion for both antimicrobial and antiparasitic activity under anaer-
obic conditions.
Independently, during the course of this work, Miyamoto et al.
[12] reported a similar approach to Mtz-triazoles, prepared by re-
action of six different 5-nitroimidazole azides with a library of al-
kynes. The compounds were prepared for testing by dilution of the
crude reaction mixtures (>85% purity by LCMS) with dimethyl
sulfoxide. This methodology bypassed the bottleneck of compound
puriﬁcation and characterization and allowed for the rapid
assessment of activity. The solutions of crude material were tested
against the parasites Giardia lamblia and Trichomonas vaginalis, the
microaerophilic bacteria Helicobacter pylori, the anaerobes
C. difﬁcile and Bacteroides fragilis and the facultative anaerobic
bacteria E. coli. It is possible that the crude mixtures contained
unreacted starting azide 3, which we have shown in this study
retains activity, and may inﬂuence the reported crude compound
potency. A key ﬁnding by Miyamoto was that Mtz-triazoles were
often active against metronidazole resistant (MtzR) strains of
T. vaginalis (47% of compounds) and G. lamblia (100% of com-
pounds), but not againstH. pylori frxA and rdxA doublemutant (1.4%
of compounds) [12]. From this result, we hypothesized that Mtz-
triazoles may possess activity against metronidazole resistant C.
difﬁcile. More recently Beena et al. described the activity of Mtz-
triazoles against the anaerobic protozoan Entamoeba histolytica
[13]. They tested a library of 10 Mtz-triazoles and found 4a, 4h, 4p
and 4q to have potent activity (IC50 ¼ 0.008e2.36 mM) against
E. histolytica HM1: IMSS [13].
We now report an expansion and advancement of these ap-
proaches with the synthesis of a small library of puriﬁed Mtz-
triazoles 4a-t (>95% purity, Scheme 1), including ten novel de-
rivatives (4b, 4c, 4f, 4g, 4i, 4j, 4l, 4o, 4s and 4t). We also explore the
antimicrobial and antiparasitic properties of the set of Mtz-
triazoles and the parent azide 3 (>95% purity) and determine
their activity against additional microbial targets that have not
previously been examined. We evaluated the activity of Mtz-
triazoles against the parasites E. histolytica and G. lamblia, multi-
ple pathogenic strains of the anaerobe C. difﬁcile, the micro-
aerophile H. pylori and the facultative anaerobic bacterial ESKAPE
pathogens E. coli, methicillin resistant S. aureus (MRSA), Klebsiella
pneumoniae, Acinetobacter baumanni and P. aeruginosa. The anti-
bacterial activity was measured against a stable MtzR C. difﬁcile
strain (CD26A54_R), the parent C. difﬁcile strain with elevated
metronidazole minimum inhibitory concentration (MIC)
(CD26A54_S) and MtzR H. pylori clinical isolates, while cytotoxicity
of the compounds was evaluated against mammalian liver (HepG2)
and kidney (HEK293) cell lines.2. Materials and methods
2.1. Synthesis of Mtz-triazole library
Mtz-triazoles were synthesized frommetronidazole via an azide
intermediate by activation of the hydroxyl group with meth-
anesulfonyl chloride (Scheme 1). Displacement of methanesulfo-
nate 2 with sodium azide provided the desired azide 3 by
nucleophilic substitution. The azide substituent was then reacted
with a library of alkynes to give 4a-t by copper-catalysed Huisgen
1,3-dipolar cycloadditionwith copper sulfate and sodium ascorbate
in methanol, with heating to 45 C and/or additional reagents
added if monitoring indicated the reaction was incomplete. All al-
kynes utilized were commercially available with the exception of
pyrazole alkyne 6. Pyrazole alkyne 6 was prepared by reacting
pyrazole 5 with propargyl bromide in the presence of potassium
carbonate and t-butylammonium bromide as a phase transfer
catalyst (Scheme 1) [14]. All compounds were characterized by 1H
and 13C NMR, LCMS and HRMS and detailed experimental pro-
cedures and characterization are provided in the supplementary
information.2.2. MIC assays
All compounds were tested for activity against a set of anaerobic
C. difﬁcile bacteria (630 ATCC BAA-1382, NAP1/027 M7404, NAP1/
027 ATCC BAA-1803, VPI10463 ATCC 43255, CD26A54_S and
CD26A54_R) and representative ESKAPE pathogens S. aureus
(MRSA ATCC 43300), E. coli (ATCC 25922), K. pneumoniae (ATCC
700603), A. baumannii (ATCC 19606) and P. aeruginosa (ATCC
27853) using a standard broth microdilution assay. Selected com-
pounds were tested for activity against H. pylori strains (26695, and
clinical isolates MtzS 13/25, MtzR 98/285 and MtzR 13/61) using
agar plate dilution, and for antimicrobial activity against twelve
Gram-positive bacterial strains: Enterococcus faecalis (VanA clinical
isolate), Enterococcus faecium (MDR VanA ATCC 51559), Strepto-
coccus pneumoniae (MDR ATCC 700677), S. aureus (MRSA ATCC
43300, MRSA clinical isolate, MRSA/DRSA clinical isolate, GISA
NARSA NRS 1, GISA NARSA NRS 17, VRSA NARSAVRS1, VRSA NARSA
VRS4 and VRSA NARSAVRS10) using broth microdilution. C. difﬁcile
strains were grown at 37 C in a COYanaerobic chamber (5% H2,10%
CO2, 85% N2). H. pylori strains were grown at 37 C under a
microaerobic atmosphere (5% O2,10% CO2). All facultative anaerobic
bacteria were grown at 37 C with normal atmospheric oxygen
levels. All experiments were performed in duplicate with metro-
nidazole, vancomycin, linezolid or colistin as positive controls for
relevant strains (see Table 1). Positive growth control of bacteria
and DMSO as well as a negative control of only media were
included for every plate. Full assay details are provided in the
supplementary information.2.3. Antiparasitic assays
Compounds were tested for antiparasitic activity against
E. histolytica (HM1:1MSS strain) and G. lamblia (WB, BRIS/87/HEPU/
713 (713) [15], BRIS/83/HEPU/106 (106) [16] and the metronidazole
resistant syngeneic line 713-M3 [15,16]) using an ATP-
bioluminescence based screen for cell growth and survival [17,18].
Assay plates were inoculated with trophozoites (5  103 parasites/
well) and incubated in the GasPak™ EZ Anaerobe Gas Generating
Pouch Systems (VWR, West Chester, PA) to maintain anaerobic
conditions throughout the incubation period. The assays were
performed in triplicate using the CellTiter-Glo Luminescent Cell
Viability Assay [17]. Metronidazole was used as a positive control.
Scheme 1. Synthesis of metronidazole-triazole conjugate library. i) MsCl, TEA, DCM, 2 C to rt, 80 min, 85% yield ii) NaN3, DMF, 50 C, 21 h, quant. yield iii) CuSO4, sodium ascorbate,
MeOH, rt or 45 C, 20 mine48 h, 9e97% iv) propargyl bromide (80% w/v in toluene), K2CO3, TBAB, rt, 3 days, 16%.
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Compounds were tested for cytotoxicity against mammalian
HepG2 and HEK293 cell lines, as detailed in the supplementary
information.3. Results and discussion
3.1. Design of metronidazole-triazole conjugate library
The Mtz-triazole library was designed to contain a variety of
structural groupswith some compounds identical to those reported
by Beena et al. (4a, 4h, 4p and 4q) [10]. Initial results against
C. difﬁcile showed that hydrophobic 4a (R ¼ phenyl) maintained
activity relative to metronidazole 1 while more hydrophilic 4p
(R ¼ hydroxyethyl) and 4q (R ¼ hydroxymethyl) lost activity.
Therefore the subsequent library was biased towards exploring
variance of the aromatic ring substitutions, extension of the posi-
tion of the aromatic ring relative to the triazole core and replace-
ment of the phenyl groupwith various heterocycles, with several of
the latter selected due to their rating in terms of medicinal chem-
istry ‘developability’ [19]. Amine 4t, and acids 4r and 4s were
included to explore the structure activity relationships of non-
aromatic ionisable groups. Compounds 4a, 4d, 4e, 4h, 4k, 4m, 4n,4q and 4rwere reported by Miyamoto [12], but 4a, 4h and 4qwere
not tested against C. difﬁcile. Compounds 4b, 4c, 4f, 4g, 4i, 4j, 4l, 4o,
4s and 4t are described for the ﬁrst time.3.2. Antimicrobial and antiparasitic activity of metronidazole-
triazole conjugates
The antimicrobial and antiparasitic spectrum of action of Mtz-
triazoles was assessed against the anaerobic bacteria C. difﬁcile
and the anaerobic parasites E. histolytica and G. lamblia (Table 1).
Variations to the phenyl group of 4a were well tolerated and ac-
tivity of 4b-e was maintained against C. difﬁcile, E. histolytica and
G. lamblia (Table 1). Phenyl derivatives 4a-ewere several fold more
active against G. lamblia than metronidazole. Pyridine 4h and
thiophene 4n heterocycles also possessed broad-spectrum activity
against C. difﬁcile, E. histolytica and G. lamblia. However, we found
that 4h was not as potent compared to metronidazole in the ATP-
bioluminescence parasite assay in contrast to the eosin-stain
method used by Beena et al. [13] The pyrazole 4g and pyrimidine
4i-j maintained activity against C. difﬁcile within one to two 2-fold
dilutions of metronidazole. Compounds 4g and 4i-jwere still active
against G. lamblia compared to metronidazole, but were several
fold less potent than the phenyl derivatives 4a-e. The pyrazole 4g
and pyrimidines 4i-j did not inhibit E. histolytica at 25 mM, showing
Table 1
Activity of Mtz-triazoles against C. difﬁcile, ESKAPE bacteria, E. histolytica and G. lamblia.
Compound MIC (mg/mL) EC50 (mM)
C. difﬁcilea ESKAPE bacteriah E. histolytica G. lamblia
630b VPI 10463e NAP1/027c NAP1/027d NAP1/027f NAP1/027g HM1:IMSS WB
MtzS MtzS MtzS MtzS MtzS MtzR MtzS MtzS
1 metronidazole 0.5 0.5 0.5 0.5 1 4 >32 5 7.9
3 azide 1 0.5 0.5 0.5 2 8 >32 2.1 1.5
4a phenyl 0.5 0.25-0.5 0.5 0.5 1 2 >32 4.2 0.25
4b p-OMe-phenyl 0.5 0.25-0.5 0.5 0.5 1 4 >32 4.8 0.27
4c p-Cl-phenyl 0.5 0.25 0.25 0.25 2 16 >32 3.6 0.20
4d p,m-Cl2-phenyl 0.5 0.5-1 1 1 1 8-16 >32 5.2 0.39
4e p-Me-phenyl 0.5 0.25 0.5 0.5 1 2 >32 3.7 0.18
4f methyl ester 1 1 1 1 2 4 >32 >25 3.0
4g pyrazole 1 1 1 1 2 4 >32 >25 4.9
4h pyridine 0.5 0.5 0.5 0.5 1 4 >32 4.6 0.74
4i 5-pyrimidine 1 1 0.5-1 1 1 4 >32 >25 3.3
4j 2-pyrimidine 2 2 2 2 2-4 4 >32 >25 1.7
4k benzyl 0.5 0.25-0.5 0.5 0.5 1 4 >32 1.9 0.70
4l CHOH-phenyl 1 0.5 1 0.5-1 2 4 >32 >25 4.4
4m CH2NMe-benzyl 2 1-2 1 2 2 8 >32 4.6 1.6
4n thiophene 0.5 0.25-0.5 0.5 0.5 1 2 >32 3.8 0.37
4o thiomorpholine >64 >64 >64 >64 >64 >64 >32 >25 >25
4p CH2CH2OH 8 8 16 8 8 16 >32 >25 >25
4q CH2OH 16 16 16-32 16 16-32 16 >32 >25 >25
4r CH2CH2COOH >64 >64 >64 >64 >64 >64 >32 >25 >25
4s COOH 64 64 64 64 >64 >64 >32 >25 >25
4t CH2NH2 >64 >64 >64 >64 >64 >64 >32 >25 >25
a MIC results determined against CD26A54_S and CD26A54_R after 48 h growth, all other C. difﬁcile strainMIC results determined at 24 h. See Supplementary Table 1 forMIC
at 24 h for CD26A54_S and CD26A54_R and at 48 h for ATCC BAA-1803. C. difﬁcileMICs are the median of at least n ¼ 4, except for CD26A54_R where n ¼ 8. ESKAPE pathogen
MICs were performed in a single concentration screen with n ¼ 3. EC50 results n ¼ 3.bATCC BAA-1382.cATCC 43255.dM7404.eATCC BAA-
1803.fCD26A54_S.gCD26A54_R.hS. aureusMRSA (ATCC 43300), E. coli (ATCC 25922), K. pneumoniae (ATCC 700603), A. baumannii (ATCC 19606) and P. aeruginosa (ATCC 27853).
A.M. Jarrad et al. / European Journal of Medicinal Chemistry 101 (2015) 96e102 99that the R group can be used as a handle to tune the selectivity of
this class towards different organisms. Compound 4k (benzyl) and
4m (CH2NMe-benzyl) maintained broad-spectrum activity but 4l
(CHOH-phenyl) was inactive against E. histolytica at 25 mM.
Several compounds were inactive, or weakly active, against all
three microorganisms at the highest concentration tested. These
included the non-aromatic thiomorpholine dioxide 4o, amine 4t
and the carboxylic acids 4r and 4s. The methyl hydroxyl 4q and
ethyl hydroxyl 4p were inactive against E. histolytica and G. lamblia
and weakly potent against C. difﬁcile, continuing the trend of
reduced activity with more polar substituents.
We also demonstrate that the parent azide 3 possesses potent
activity against C. difﬁcile, E. histolytica and G. lamblia. Therefore,
when assessing combinatorial-like libraries of crude material for
biological activity, the activity of any unreacted parent compounds
is an important consideration, particularly when the compound
warhead is maintained.
The MICs of 1, 3 and 4a-t were >32 mg/mL against the repre-
sentative ESKAPE pathogens (MRSA, E. coli, K. pneumoniae,
A. baumannii and P. aeruginosa) tested under aerobic conditions. In
addition, the MIC values of a subset of compounds (metronidazole
1, azide 3, 4a (phenyl) and 4q (CH2OH)) were all >64 mg/mL against
a panel of 8 additional drug resistant S. aureus strains, vancomycin
resistant E. faecalis, vancomycin resistant E. faecium and multidrug
resistant S. pneumoniae. This lack of activity is contrary to Beena's
report, but consistent with the reported inactivity of 378 Mtz-
triazoles against E. coli in Miyamoto's study, and the inactivity of
metronidazole against facultative anaerobic bacteria.3.3. Activity of metronidazole-triazole conjugates against C. difﬁcile
strain panel
The activity of the Mtz-triazoles did not vary signiﬁcantly
against multiple strains of C. difﬁcile, including two majorpathogenic strains of NAP1/027 and a VPI10463 strain associated
with epidemics (Table 1). The MICs of individual compounds typi-
cally remained within one 2-fold dilution against the four strains of
C. difﬁcile tested. This is important, as viable drug candidates must
possess appropriate broad strain coverage. A review of antibiotic
drug candidates in development found that activity against multi-
ple strains of C. difﬁcile could vary substantially [20]. This can be
explained since C. difﬁcile has a highly mobile, mosaic genome and
there is wide strain diversity between isolates [21,22]. Isolates can
be divided across ﬁve main phylogenetic clades, multiple ribotypes
and toxinotypes [23]. Recently, genomic epidemiology studies
examining and tracking C. difﬁcile outbreaks in Europe found that a
high proportion of strains causing infection were not related to
prior infectious strains [22]. Therefore, there is a large pool of
genetically diverse strains in the community and selection and
spread of intrinsically resistant strains could occur. However, the
broad-strain activity of Mtz-triazoles against C. difﬁcile in this study
encourages further development of this class.3.4. Activity of metronidazole-triazole conjugates against
metronidazole resistant C. difﬁcile
While metronidazole resistance has been reported in the clinic
[9,24], performing antimicrobial susceptibility testing against
resistant C. difﬁcile isolates is problematic since the resistance
phenotype is unstable and often reported to be lost on freeze thaw
cycles or on passaging of the isolates [5]. However, Lynch et al. have
reported a stable metronidazole resistant (MtzR) C. difﬁcile clone
[25]. The activity of Mtz-triazoles was assessed against this stable
MtzR strain of C. difﬁcile (CD26A54_R) and the parent metronida-
zole sensitive (MtzS) (CD26A54_S) strain, which lost the metroni-
dazole resistance on freeze thawing, but still retained a slightly
elevated MIC value to metronidazole compared to the control MtzS
NAP1/027 strain. The MIC to metronidazole in BHIS broth at 48 h
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BAKHS (4 mg/mL vs 48 mg/mL), similar to values reported by Chong
et al. (8 mg/mL vs > 32 mg/mL) [26].
The resistance to metronidazole became more apparent on in-
cubation in broth for 48 h (MIC ¼ 2 mg/mL after 24 h incubation vs
MIC ¼ 4 mg/mL after 48 h) (Supplementary Table 1). In contrast,
MICs against the control MtzS NAP1/027 strain ATCC 1803 did not
change signiﬁcantly between 24 h and 48 h (Supplementary
Table 1). Although several compounds (4a, 4e and 4n) were
active against MtzR C. difﬁcile at 1 dilution lower than metronida-
zole (MIC ¼ 2 mg/mL vs 4 mg/mL), none of the Mtz-triazoles were
active against MtzR C. difﬁcile at levels comparable to the activity of
metronidazole against MtzS strains (MIC ¼ 0.5 mg/mL). Reduced
activity against the parent C. difﬁcile strain CD26A54_S with inter-
mediary metronidazole susceptibility was also observed.3.5. Activity of metronidazole-triazole conjugates against
additional G. lamblia strains including metronidazole resistant G.
lamblia
Selected compounds (4a-f, 4h, 4k-n) were tested against two
additional strains of MtzS G. lamblia (106 and 713) and one MtzR
strain (713-M3) derived from the parent MtzS strain 713 (Table 2).
The Mtz-triazoles displayed similar activity against the additional
MtzS strains (106 and 713) compared to G. lamblia strain WB.
Encouragingly, the Mtz-triazoles were all more potent than
metronidazole against MtzR G. lamblia 713-M3. However, with the
exception of 4d, all of the Mtz-triazoles lost activity against the
MtzR G. lamblia 713-M3 when compared to the parent MtzS strain
713, similar to the loss of activity against MtzR C. difﬁcile. Mtz-
triazoles of scaffold 4 were also all observed by Miyamoto et al.
to lose activity against MtzR G. lamblia 713-M3 and 106-2ID10.
However, while activity diminished against the MtzR 713M strain,
the Mtz-triazoles were often still much more potent than metro-
nidazole itself, meaning that the EC50 remained within a thera-
peutically meaningful window.
The activities of puriﬁed Mtz-triazoles (>95% purity) against
G. lamblia strains 106, 713 and 713M were compared with the
literature activities [12] determined with crude reaction mixtures
(Supplementary Table 3). The activities were generally in close
agreement, supporting the methodology used by Miyamoto [12],
although a 3.7e8 fold difference was observed for Mtz-triazoles 4d,
4e and 4m against 1 strain of G. lamblia.Table 2
EC50 of selected Mtz-triazoles against G. lamblia strains. The EC50 values for
G. lamblia WB strain are shown from Table 3 for comparison.
Compound EC50 (mM)
G. lamblia
WB 106 713 713M
MtzS MtzS MtzS MtzR
1 metronidazole 7.9 2.8 2.3 17
4a phenyl 0.25 0.28 0.16 2.3
4b p-OMe-phenyl 0.27 0.64 0.64 1.0
4c p-Cl-phenyl 0.20 0.89 1.2 3.5
4d p,m-Cl2-phenyl 0.39 1.1 2.5 1.2
4e p-Me-phenyl 0.18 0.29 0.29 1.0
4f methyl ester 3.0 2.0 1.8 3.1
4h pyridine 0.74 0.38 0.28 0.95
4k benzyl 0.70 0.51 0.32 1.1
4l CHOH-phenyl 4.4 2.2 2.4 3.0
4m CH2NMe-benzyl 1.6 1.1 0.71 2.2
4n thiophene 0.37 0.34 0.18 0.93.6. Activity of metronidazole-triazole conjugates against
metronidazole resistant H. pylori
Selected compounds (4f-h, 4m and 4s) were tested against a
panel of H. pylori strains using the CLSI agar dilution susceptibility
method (Table 3) [27]. These strains included the reference strain
26695 and three clinical isolates 13/25 (metronidazole E-test
MIC ¼ 2 mg/mL), 98/285 (E-test MIC ¼ 24 mg/mL) and 13/61 (E-test
MIC ¼ 256 mg/mL) with a range of resistance levels to metronida-
zole determined by the E-test. The susceptibilities of the strains to
metronidazole determined by the agar dilution method differed
from the susceptibilities obtained from the E-test as has been
described previously [28]. The methyl ester 4f was weakly active
against H. pylori, while the carboxylic acid 4s was inactive against
all H. pylori strains as observed with E. histolytica and G. lamblia as
well. Compounds 4g, 4h and 4m were more active than metroni-
dazole against the MtzS strains (26695 and clinical isolate 13/25)
and 1e2 dilutionsmore active thanmetronidazole against theMtzR
strains (clinical isolates 98/285 and 13/61) but they could not
completely overcome metronidazole resistance, similar to the loss
of activity against metronidazole resistant C. difﬁcile.3.7. Cytotoxicity
All compounds, including metronidazole 1, azide 3, and 4a-t
showed no cytotoxicity against HepG2 and HEK293 cells at con-
centrations up to 100 mM (CC50). This is consistent with the ﬁndings
by Miyamoto et al. which did not observe cytotoxicity against HeLa
cells at 50 mM [12].3.8. Relationship of compound activity with compound properties
In order to understand the relationship between compound
properties and activity, compound properties including logP (or
logD at pH ¼ 7.4), molecular weight, topological polar surface area
(tPSA), and predicted solubility (logS) were examined for correla-
tionwith activity against MtzS strains of C. difﬁcile, E. histolytica and
G. lamblia, with the activity expressed as pMIC (-log10MIC) or pEC50
(-log10EC50)) (Supplementary Table 4). Inactive compounds were
included in the analysis at the highest concentration of compound
tested. A correlation can be observed between the logD values and
the activity against G. lamblia (with R2 (linear regression) ¼ 0.84,
Supplementary Fig. 1) (Fig. 2). The logD of the most potent com-
pounds (4a-e, 4h, 4k and 4n) against G. lamblia is between 1.5 and
3.0, with activity decreasing with lower logD. In contrast, only a
mild correlation could be detected between logD and the activity
against C. difﬁcile (R2 ¼ 0.68, Supplementary Fig. 1) and no corre-
lation for activity against E. histolytica (R2 ¼ 0.48, Supplementary
Fig. 1). This might explain why the compounds with aromaticTable 3
MIC of selected Mtz-triazoles against H. pylori strains.
Compound MIC (mg/mL)
H. pylori
26695 13/25a 98/285a 13/61a
MtzS MtzS MtzR MtzR
1 metronidazole 8 4-8 64 32-64
4f methyl ester 32-64 32-64 64->64 64->64
4g pyrazole 2-4 2 16-32 16-32
4h pyridine 2 1 32 16
4m CH2NMe-benzyl 4 2 16->64 16
4s COOH >64 >64 >64 >64
a clinical isolate.
Fig. 2. Correlation of activity against G. lamblia, E. histolytica and C. difﬁcile with logD.
Compounds with activity against parasites (EC50 < 25 mM) and C . difﬁcile (MIC  8 mg/
mL) have pEC50 or pMIC > 5.0.
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G. lamblia than E. histolytica and C. difﬁcile. Increasing the hydro-
phobicity (logD) of compounds to improve potency is generally
considered undesirable in drug development due to the tendency
for increased metabolism [29] and increased promiscuity [30].
However, in this case the antibiotic metronidazole has a low logD to
begin with, such that the relatively higher logD of the compounds
explored in this study does not place the compounds in an unde-
sirable chemical space. On the other hand, the site of infection of
G. lamblia is the small intestine, where low (<1) or high (>3) logD
values [29], associated with reduced systemic uptake, might be
beneﬁcial for efﬁcacy. However, metronidazole is 100% oral
bioavailable [31] and so the importance of bioavailability for in vivo
efﬁcacy against G. lamblia infections is unclear.4. Conclusion
Mtz-triazoles were synthesized and assessed for activity against
the anaerobe C. difﬁcile, microaerophile H. pylori, the parasites
E. histolytica and G. lamblia as well as facultative anaerobic Gram-
positive and Gram-negative bacteria. While no activity was
observed against the facultative anaerobic bacteria, nine com-
poundswere identiﬁedwith potent broad spectrum activity against
anaerobic organisms, while having no cytotoxicity against
mammalian cell lines. Hydrophobic R groups such as the benzyl 4k,
varyingly substituted phenyl derivatives 4a-e and heterocyclic R
groups such as pyridine 4h and thiophene 4n were well tolerated
and favored broad spectrum anaerobic activity. In contrast, polar R
groups including pyrimidines 4i-j, carboxylic acids 4p and 4r and
methyl amine 4t either resulted in loss of broad spectrum activity
or were inactive against all organisms tested.
While active Mtz-triazoles displayed a narrow MIC range
against multiple strains of C. difﬁcile and G. lamblia, there was
metronidazole cross resistance against the stable MtzR C. difﬁcile
strain CD26A54_R, MtzR G. lamblia strain 713M and clinical isolates
of MtzR H. pylori. Mtz-triazoles 4a-t generally lost activity against
MtzR C. difﬁcile, MtzR G. lamblia and MtzR H. pylori. However, since
the Mtz-triazoles were often much more potent than metronida-
zole against G. lamblia, the EC50 remained within a therapeutically
meaningful window. It is possible that surveying a more diverse
chemical space of R group substituents or using alternative 5-
nitroimidazole scaffolds could provide access to Mtz-triazoles
that are even more potent and therefore active against MtzRstrains of C. difﬁcile and G. lamblia. Future work will focus on
identifying such compounds and explore their in vivo efﬁcacy
against anaerobic pathogens.
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